Press Releases
Press Releases
Personalised Medicine and Diagnostics Europe 2011
Innovate in an era of cost-effectiveness: Realise the value of personalised medicine Discover how to strengthen your drug pipeline with companion diagnostics How to access the market Hear about the expectation of the pharmaceutical and diagnostics industry and...
Press Releases
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY
King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. announced that King has resubmitted a New Drug Application (NDA) for REMOXY (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by Pain Therapeutics...
Press Releases
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery
Sanofi-aventis and Ascendis Pharma (Ascendis) announced a global licensing and patent transfer agreement on Ascendisโ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion,...
Press Releases
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results, published in The New England Journal of Medicine, showed apixaban was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients...
Press Releases
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis has received approval from Japan's Ministry of Health, Labour and Welfare to offer Tasignaยฎ (nilotinib) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The...
Press Releases
Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
Eli Lilly and Company announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on...
Press Releases
Merck KGaA and sanofi-aventis Sign Agreement to Jointly Investigate Novel Combinations Against Cancer
Merck KGaA announced today that it has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which its division Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















